Eirhub’s Post

💊 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗘𝘅𝗽𝗼𝗿𝘁 𝗟𝗲𝗮𝗱𝗲𝗿𝘀 🚢 🌐 The #pharmaceutical #industry stands as one of the largest and most crucial sectors globally, with its export value reaching staggering figures. 🥇 In 2023, #Germany continued to demonstrate its dominance, with an exported value totaling $119.3 billion, highlighting its consistent performance at the forefront of the pharmaceutical export market. 🎖 Despite fluctuations, the #USA and #Switzerland maintained their positions as the leading exporters, showcasing steady growth over the years. 🎯 #Belgium experienced a significant decline in exported value in 2023 compared to the previous year, falling to $82.5 billion. Conversely, #Italy displayed a noticeable increase, reaching $50.3 billion in 2023, showcasing a positive growth trajectory. ✨ Furthermore, the #Netherlands witnessed a remarkable surge in pharmaceutical exports, more than doubling its exported value from $28.6 billion in 2022 to $57.4 billion in 2023, reflecting a substantial shift in its pharmaceutical trade landscape. 🏆 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗘𝘅𝗽𝗼𝗿𝘁 𝗩𝗮𝗹𝘂𝗲 𝗶𝗻 𝟮𝟬𝟮𝟯 ($𝗕): 1. Germany 119.3 2. Switzerland 98.8 3. USA 90.3 4. Belgium 82.5 5. Ireland 71.7 6. Netherlands 57.4 7. Italy 50.3 8. France 38.0 9. UK 27.5 10. Spain 22.1 11. Denmark 21.0 12. India 21.0 (Estimated) 13. Slovenia 20.3 14. Austria 17.6 15. Sweden 13.62 💱 Source: Trade Map (ITC calculations based on UN COMTRADE and ITC statistics.) #pharmaceutical #pharmaindustry #biotechnology #medicine #healthcare #top10 #exporter #exportimport #trading

💊𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗘𝘅𝗽𝗼𝗿𝘁 𝗟𝗲𝗮𝗱𝗲𝗿𝘀 🚢 🌐 The #pharmaceutical #industry stands as one of the largest and most crucial sectors globally, with its export value reaching staggering figures. 🥇 In 2023, #Germany continued to demonstrate its dominance, with an exported value totaling $119.3 billion, highlighting its consistent performance at the forefront of the pharmaceutical export market. 🎖 Despite fluctuations, the #USA and #Switzerland maintained their positions as the leading exporters, showcasing steady growth over the years. 🎯 #Belgium experienced a significant decline in exported value in 2023 compared to the previous year, falling to $82.5 billion. Conversely, #Italy displayed a noticeable increase, reaching $50.3 billion in 2023, showcasing a positive growth trajectory. ✨ Furthermore, the #Netherlands witnessed a remarkable surge in pharmaceutical exports, more than doubling its exported value from $28.6 billion in 2022 to $57.4 billion in 2023, reflecting a substantial shift in its pharmaceutical trade landscape. 🏆 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗘𝘅𝗽𝗼𝗿𝘁 𝗩𝗮𝗹𝘂𝗲 𝗶𝗻 𝟮𝟬𝟮𝟯 ($𝗕): 1. Germany 119.3 2. Switzerland 98.8 3. USA 90.3 4. Belgium 82.5 5. Ireland 71.7 6. Netherlands 57.4 7. Italy 50.3 8. France 38.0 9. UK 27.5 10. Spain 22.1 11. Denmark 21.0 12. Slovenia 20.3 13. Austria 17.6 14. Sweden 13.62 15. Singapore 11.0 💱 Source: Trade Map (ITC calculations based on UN COMTRADE and ITC statistics.) #pharmaceutical #pharmaindustry #biotechnology #medicine #healthcare #top10 #exporter #exportimport #trading

#GenericDrugs Made in #India Rely Heavily on #Chinese-Made Ingredients - Bloomberg US Leans on India’s Pharma Industry to Snub #China .There’s Just One Catch Report reveals close ties between companies in India and China Large generic drugmaker gets 55% of #rawmaterials from China Anna EdneyFebruary 5, 2024 at 6:00 AM EST Pills move through a sorting machine at a pharmaceutical plant in Visakhapatnam, India. Photographer: Sara Hylton/Bloomberg The Biden administration embraced a plan from India’s government last year to edge China out of its position as a leader in making ingredients for generic pharmaceuticals sold in the US. But a new report shows that much of those ingredients are likely still coming from China anyway.

Asrar Qureshi's Blog Post #827 is published in Pharma Veterans. Please read it here. https://lnkd.in/d-9AwmiS #asrarqureshi #pharmaveterans #pharmaceuticalindustry #export #drap #tdap #strategy #blogpost827

Pharmaceutical exports on track for accelerated growth Day #71 of covering Pharma Developments. 💊News Buzz.. Indian Pharma exports to grow at around 11% and reach $31 billion in FY25. 💊Where are we exporting to.? More than 50% of exports last year were to highly regulated markets like North America and Europe. 💊Major surge of exports Even when there were a lot of challenges pharmaceutical exports to the U.S. increased 15% to more than $8 billion, while the exports to the U.K. were 21% higher at $783 million. 💊What was our growth rate in FY24.? We grew by 10% in FY24 to hit $27.8 billion. I will provide the source of the article in the comment section below. By the way today is the 71st day of me deep diving into the pharmaceutical industry. I will be sharing insights from this industry on a regular basis. So please do follow me (Krishna Raj K) for such insights. #finance #Linkedin #India

Myth Buster: The Indian Pharma Market is flawless and faces no challenges. 💊🌍 ✅ Indian Pharma Market is valued at US$ 50 billion and projected to grow by 8-10% in FY 2023-24. ✅ India holds a 5.71% share in the global pharmaceutical market. ✅ Formulations and biologicals make up 72.54% of India's pharmaceutical exports. ✅ 2/3rds of Indian pharma exports go to North America, Europe, and Africa. But let's bust some myths! 🚫💡 🔍 Myth 1: Quality concerns due to Chinese-made ingredients.  - Fact: There have been concerns regarding the reliance on Chinese ingredients for generic drugs, raising quality issues in the US market. 🔍 Myth 2: Challenges in semi-regulated markets. - Fact: Semi-regulated markets face challenges as they lack complete government regulation and governance. My opinion: To overcome these challenges, India needs to focus on diversifying its supply chain and fostering domestic production of ingredients. Strengthening quality control measures and regulatory frameworks would ensure a reliable and self-sustainable pharma market. 💪🌟 What are your thoughts on these myths and the future of the Indian Pharma Market? Share your opinions! 💭✨ #PharmaMarket #IndianPharma #FactCheck #SupplyChain #QualityContro #PharmaMarket #IndianPharma #FactCheck #SupplyChain #QualityControl #MythBuster #GlobalPharmaceuticalMarket #PharmaExports #RegulatoryFrameworks #DomesticProduction 

The Role of Imports in India's Pharma Sector 🚢 While India's pharmaceutical sector boasts of its vast production capabilities, it's intricately linked to the global supply chain, especially when it comes to raw materials and active pharmaceutical ingredients (APIs). The delicate balance of imports ensures the steady production of a diverse range of medicines. Importance of Raw Materials & APIs 🧪: APIs are the heart of drug manufacturing, determining the efficacy and safety of medicines. Over 60% of India's APIs are imported, underscoring the sector's global interdependence. Countries of Import 🌏: China stands as the dominant supplier, fueling India's pharma factories with essential ingredients. Other nations, including the US, Germany, and Italy, play pivotal roles, providing specialized raw materials. Impact on Drug Pricing 💰: The reliance on imports directly influences drug prices. Global market dynamics can lead to fluctuations in the domestic market. Strategies like stockpiling and diversifying import sources are being explored to ensure price stability. #PharmaImports #APIs #GlobalPharma #DrugPricing #MedicineSupplyChain

What exactly does 'making your pharmaceutical supply chain more resilient' actually mean? For those in pharma like me, I'm sure you'll all agree, that this something we've all been told to do since Covid times. So what is it exactly? Well, to me and those many others, I think the primary implications of becoming resilient, is to reduce one's dependencies on China. Wherever possible. Pen G is certainly one of them. (Pen G is one of the building blocks for semi-synthetic penicillin and an indirect contributor in the production of cephalosporins.) Funnily, India is a massive producer, consumer and exporter of finished dosages such Amoxicillin, Ampicillin and Ceftriaxone which remain essential therapies in modern medicine. Yet, is heavily import dependent for key intermediates such as Pen G, 6-APA, 7-ACA needed in the making of the APIs. Hence, no surprise to see AUROBINDO PHARMA LTD putting one step forward in truly looking to make the supply chain more resilient! Will it be a game changer? I feel it's a bit of a yes and no here. It'll certainly make Aurobindo a much more dominant global figure in these therapeutic segments, and would surely up the ante with the likes of North China Pharmaceutical Company. Ltd and CSPC Pharmaceutical Group for example, some of the largest producers of these key raw materials. It'll also disrupt any loopholes that are helping breed Chinese cartels and price fixing models. However, with 60% of Aurobindo's production destined for their captive consumption, maybe a minimal 10% for exports, that would leave only about 30% for the bulk of Indian beta-lactam and cephalosporin API producers. Would that be sufficient enough to make India, as a whole, globally competitive would remain to be seen. The critics of the PLI scheme may have a lot to criticize and please don't get them wrong - they have the full right to do so, if they find valid enough reasons. But one thing that surely can't be denied is that, even though we're still very far from removing our total dependencies from China on these key raw materials, it does lighten some of the burden and most essentially, helps India take a few steps forward on the global landscape. Disruption can sometimes be good. Even in the supply chain! Because SOME competition will always be better than NO competition. And I think, in the end, that's what 'supply chain resilience' is all about'. #masterplan #pharma #API #FDF #manufacturing #rawmaterials #Penicillin #Cephalosporin #global

The exponentially growing pharmaceutical industry has a significant role in the overall global economy. This $1.5 trillion industry holds around 10% of the worldwide health economy. In terms of product category, the pharmaceutical industry is basically divided into two classes: one is innovative and the other is generic, with an individual share of 56% and 44%, respectively. The innovative products market is mostly controlled by the developed world as it is embedded in advanced research and technology, which are highly expensive. On the other hand, a few developing countries are doing exceptionally well in generic markets by offering quality products at affordable prices. Generics are the true copy of the innovator after patent expiration, and it involves little basic research. These are also easy to offer, as the molecule is already established by the innovator. Global sales from worldwide exports of drugs and medicines totalled $426.8 billion last year, where Germany, Switzerland, the US, Belgium and Ireland were unparalleled with their innovative product exports. On the other hand, India, China, Mexico, South Korea, Singapore, Israel, Turkey, and Bangladesh had a significant presence in generic exports. As an emerging country, Bangladesh is increasing its share in pharmaceutical export and currently ranks 67th in the global pharma export market. It is also encouraging that during the last six years, the annual export volume has almost doubled, with a current volume of around $190 million per year.

Emerging trends in pharmaceuticals and chemicals